



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Peter	Re Application of: r Lind, Torsten Sejlitz, Gabriel Voge la S. Wood	ili,
Seri	al No.: Not yet assigned	Group Art Unit: Not yet assigned
Filin	ng Date: Herewith	Examiner: Not yet assigned
For:	Novel G Protein-Coupled Recep	otors
		EXPRESS MAIL LABEL NO: EL531276375US DATE OF DEPOSIT: May 8, 2001
Box	☑ Patent Application☐ Provisional ☐ Design	
	eant Commissioner for Patents ington DC 20231	
Sir:		
	PATENT APPLICATI	ON TRANSMITTAL LETTER
	Transmitted herewith for filing, ple	ease find
\boxtimes	A Utility Patent Application under	37 C.F.R. 1.53(b).
	It is a continuing application, as fol	lows:
	☐ continuation ☐ divisional ☐/	ontinuation-in-part of prior application number
	A Provisional Patent Application u	nder 37 C.F.R. 1.53(c).
	A Design Patent Application (subm	• •
	Request for Nonpublication. The	invention(s) disclosed in the present application

filed herewith has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing. Thus, pursuant to 35 U.S.C. §122(b)(2)(B)(i), Applicant(s) request that the above-identified patent application not be published.

Includ	ing the	followii	ng:	
	Provisional Application Cover Sheet.			
\boxtimes	New o	r Revise	ed Specification, including pages 1 to 97 containing:	
	\boxtimes	Specif	ication	
	\boxtimes	Claims	S	
	\boxtimes	Abstract		
		Substitute Specification, including Claims and Abstract.		
			The present application is a continuation application of Application Nofiled The present application includes the Specification of the parent application which has been revised in accordance with the amendments filed in the parent application. Since none of those amendments incorporate new matter into the parent application, the present revised Specification also does not include new matter.	
			The present application is a continuation application of Application Nofiled, which in turn is a continuation-in-part of Application Nofiled The present application includes the Specification of the parent application which has been revised in accordance with the amendments filed in the parent application. Although the amendments in the parent C-I-P application may have incorporated new matter, since those are the only revisions included in the present application, the present application includes no new matter in relation to the parent application.	
	, inc	luding !	ier application Serial NoFiled	

	oath or declaration for such earlier application and all drawings and appendices. Such earlier application is hereby incorporated into the present application by reference.
	Please enter the following amendment to the Specification under the Cross-Reference to Related Applications section (or create such a section): "This Application: ☐ is a continuation of ☐ is a divisional of ☐ claims benefit of U.S. provisional Application Serial No
	· ·
	Signed Statement attached deleting inventor(s) named in the prior application.
	A Preliminary Amendment.
	Sheets of Formal Informal Drawings.
	☐ Drawing view to publish: Figure
	Petition to Accept Photographic Drawings.
	☐ Petition Fee
×	An ☐ Executed ☑ Unexecuted Declaration or Oath and Power of Attorney.
	An Associate Power of Attorney.
	An Executed Copy of Executed Assignment of the Invention to
	A Recordation Form Cover Sheet.
	Recordation Fee - \$40.00.
	The prior application is assigned of record to
	Priority is claimed under 35 U.S.C. § 119 of Patent Application No.
	filed in(country).

DOCKET N	NO.: 00231regUS - 4 -	PATENT
	 ☐ A Certified Copy of each of the above applications for whi is claimed: ☐ is enclosed. ☐ has been filed in prior application Serial No 	
	An Executed or Copy of Executed Earlier Statement Claim Entity Status under 37 C.F.R. 1.9 and 1.27 is enclosed. has been filed in prior application Serial No	ing Small
-	• • •	
\boxtimes	Diskette Containing DNA/Amino Acid Sequence Information.	
\boxtimes	Statement to Support Submission of DNA/Amino Acid Sequence	Information.
	The computer readable form in this application, is identified in Application Serial Number, filed accordance with 37 CFR 1.821(e), please use the first-filed, or only computer readable form filed in that application as the readable form for the instant application. It is understood that the Trademark Office will make the necessary change in application in filing date for the computer readable form that will be used for the application. A paper copy of the Sequence Listing is included originally-filed specification of the instant application, include separately filed preliminary amendment for incorporation into the specification.	In last-filed computer Patent and number and instant in the
	Information Disclosure Statement. ☐ Attached Form 1449. ☐ Copies of each of the references listed on the attached Formare enclosed herewith.	m P TO-1449
	A copy of Petition for Extension of Time as filed in the prior case.	

Appended Material as follows:

DOCI	KET N	O.: 00231regUS - 5 -	PATENT
		Return Receipt Postcard (should be specifically itemized).	
	\boxtimes	Other as follows: <u>Sequence Listing Pages 1-3.</u>	
	FEE C	CALCULATION:	
		Cancel in this application original claimsof the price	or

application before calculating the filing fee. (At least one original

independent claim must be retained for filing purposes.)

*******	*********	*****	SMAI	L ENTITY	NOT SM	MALL ENTITY
			RATE	FEE	RATE	FEE
PROVISIONAL A	PPLICATION		\$75.00	\$	\$150.00	\$
DESIGN APPLICA	ATION		\$160.00	\$	\$320.00	\$
UTILITY APPLIC	ATIONS BASE FI	EE	\$355.00	\$	\$710.00	\$ 710.00
UTILITY APPLIC CALCULATED A AMENDMENTS						
***************************************	No. Filed	No. Extra				********
TOTAL CLAIMS	142 - 20 =	122	\$9 each	\$	\$18 each	\$2,196.00
INDEP. CLAIMS	14 - 3 =	11	\$40 each	\$	\$80 each	\$1,120.00
CLAIMS INDEP. 14 - 3 = 11 CLAIMS FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM			\$135	\$	\$270	\$ 270.00
ADDITIONAL FILING FEE			*********	\$	18888888	\$
TOTAL FILING FEE DUE				\$	 	\$4,296.00

\boxtimes	A Check is enclosed in the amount of \$4,296.00.
-------------	--

\boxtimes	The Commissioner is authorized to charge payment of the following fees and to
	refund any overpayment associated with this communication or during the pendency of this application to deposit account 23-3050. This sheet is provided in duplicate.

	The	foregoing	amount	due.
--	-----	-----------	--------	------

Any additional filing fees required, including fees for the presentation of extra claims under 37 C.F.R. 1.16.

\boxtimes	Any additional patent application processing fees under 37 C.F.R. 1.17 or
	1.20(d).
	The issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance.

The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to deposit account 23-3050. This sheet is provided in duplicate.

SHOULD ANY DEFICIENCIES APPEAR with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the United States Patent and Trademark Office is respectfully requested to promptly notify the undersigned.

Date: 8 MAY 2001

Registration No. 38,534

Paul K. Legaard

Woodcock Washburn Kurtz Mackiewicz & Norris LLP One Liberty Place - 46th Floor Philadelphia PA 19103 Telephone: (215) 568-3100

Facsimile: (215) 568-3439

© 1997 WWKMN

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Peter Lind, Torsten Sejlitz, Gabriel Vogeli, and Linda S. Wood

Serial No.: Not yet assigned

Group Art Unit: Not yet assigned

Filing Date: Herewith

Examiner: Not yet assigned

For: NOVEL G PROTEIN-COUPLED RECEPTORS

BOX SEQUENCE

Assistant Commissioner for Patents Washington DC 20231

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825

×	I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the
	contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.
	I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.
	I hereby state that the submission filed in accordance with 37 CFR §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.
	I hereby state that the amendments, made in accordance with 37 CFR §1.825(a), included in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.
	I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.

I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(d), contains identical data to that originally filed.

Date:

8 MAY 2001

Paul K. Legaard

Registration No. 38,534

Woodcock Washburn Kurtz Mackiewicz & Norris LLP One Liberty Place - 46th Floor Philadelphia PA 19103 Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 1997 WWKMN